Cord blood (CB) transplantation has greatly extended availability of a hematopoietic cell transplant (HCT) to patients who would not otherwise have received this curative treatment. CB has several advantages over bone marrow (BM) and mobilized peripheral blood (mPB), including ease and safety of collection, ready availability, and lessened acute and chronic graft vs. host disease (GVHD). However, a disadvantage with CB is low numbers of nucleated cells, hematopoietic progenitors (HPC), and likely stem cells (HSC), compared with BM or mPB, which has translated into increase risk of graft failure, delayed engraftment, and delayed immune reconstitution. Based on our published laboratory and preclinical animal model studies, preliminary clinical data, and mechanistic studies on CD26/Dipeptidylpeptidase (DPP) IV activities reported herein, we believe that inhibition of CD26/DPPIV will significantly enhance engraftment capability of limiting numbers of human CB cells, and accelerate time to engraftment of single CB units. This multi-PI grant proposes the following specific aims:
Aim 1 : Conduct a multicenter phase II clinical trial to assess efficacy and safety of systemic inhibition of CD26/DPPIV using sitagliptin, to enhance engraftment of single CB units in adults with hematological cancers. Hypothesis: Inhibition of CD26/DPPIV by systemic administration of CD26 inhibitor sitagliptin will enhance engraftment, without negatively impacting relatively lower levels of GVHD associated with single CB transplantation. Primary Objective: Evaluate proportion of patients with neutrophil recovery by day +30 after transplant as a measure of speed of engraftment. Using an optimal two-stage design, <50% of patients engrafting by day +30 will be considered unacceptable (null hypothesis;H0: p0<0.5), while 70% or more engrafting will be considered worthy of further study (alternate hypothesis: H1: p1e0.7).
Sub aims are: a) Evaluate time to platelet engraftment, patient survival, graft failure, relapse rate, acute and chronic GVHD levels;b) Use correlative assays to assess recovery of immune cells through phenotypic and functional analysis;and c) Assess blood levels of CD26/DPPIV, and hematopoietically relevant cytokines.
Aim 2 : Evaluate how CD26/DPPIV mechanistically regulates hematopoiesis, using cell culture and biochemical studies on mouse and human cytokines and with cells from mouse BM and human CB. Hypothesis: CD26/DPPIV regulates hematopoiesis through: its specific enzymatic capability to truncate and inactivate different hematopoietically active cytokines. We will compare results to clinical study in Aim 1 to better understand and utilize this new treatment modality.
Sub aims i nclude: a) Evaluate how GM-CSF, G-CSF, IL-3 and EPO truncated by CD26/DPPIV, compared to full length form, signal intracellularly;b) Determine if systemic administration of sitagliptin to mice enhances homing of HSC and influences cytokine production;and c) Study other molecules for CD26/DPPIV truncation and activity.

Public Health Relevance

Cord blood transplantation is a viable treatment, but one disadvantage is the limiting number of cells in single cord blood collections, especially for adult recipients. By understanding how a cell surface enzyme, CD26, regulates blood cell production, and by specifically inhibiting this enzyme systemically in recipients of cord blood transplantation, we believe that donor cell engraftment will be greatly enhanced in adult recipients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL112669-03
Application #
8670014
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Thomas, John
Project Start
2012-03-01
Project End
2017-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
3
Fiscal Year
2014
Total Cost
$1,394,744
Indirect Cost
$500,677
Name
Indiana University-Purdue University at Indianapolis
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Broxmeyer, Hal E; Pelus, Louis M (2014) Inhibition of DPP4/CD26 and dmPGE? treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 53:34-8
Ou, Xuan; Lee, Man Ryul; Huang, Xinxin et al. (2014) SIRT1 positively regulates autophagy and mitochondria function in embryonic stem cells under oxidative stress. Stem Cells 32:1183-94
Broxmeyer, Hal E (2014) Inhibiting HDAC for human hematopoietic stem cell expansion. J Clin Invest 124:2365-8
Aljitawi, Omar S; Xiao, Yinghua; Eskew, Jeff D et al. (2014) Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34ýýý cells in a murine model of umbilical cord blood transplantation. Blood Cells Mol Dis 52:59-67
Velez de Mendizabal, Nieves; Strother, Robert M; Farag, Sherif S et al. (2014) Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation. Clin Pharmacokinet 53:247-59
Ou, Xuan; O'Leary, Heather A; Broxmeyer, Hal E (2013) Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood 122:161-9
O'Leary, Heather; Ou, Xuan; Broxmeyer, Hal E (2013) The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr Opin Hematol 20:314-9
Broxmeyer, Hal E; Mor-Vaknin, Nirit; Kappes, Ferdinand et al. (2013) Concise review: role of DEK in stem/progenitor cell biology. Stem Cells 31:1447-53
Farag, Sherif S; Srivastava, Shivani; Messina-Graham, Steven et al. (2013) In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 22:1007-15
Broxmeyer, Hal E (2013) Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med 210:205-8